ArticleAnnals of surgical oncology2025
Anatomical Classification and Staging Systems of Borderline Resectable and Locally Advanced Pancreatic Cancer-A Subgroup Analysis of the NORPACT-2 Trial.
Article in Annals of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundThis study aims to provide a detailed understanding of resectability and prognosis within anatomical subgroups of borderline resectable pancreatic cancer (BRPC) and locally advanced pancreatic cancer (LAPC) on the basis of established classification systems. PATIENTS AND
methodsPatients with BRPC/LAPC, defined by National Comprehensive Cancer Network (NCCN) criteria, were prospectively included from 2018 to 2020. BRPC was subcategorized by vascular involvement and LAPC by the Louisville (Lv) classification system, and both cohorts were reclassified according to the Dutch (DPCG) criteria. NCCN-defined primary resectable pancreatic cancer (PC) cases that met DPCG-BRPC criteria were included in the analysis.
resultsIn total, 228 patients (96 NCCN-BRPC, 92 NCCN-LAPC, and 40 reclassified from NNCN primary resectable PC to DPCG-BRPC) were included. NCCN-BRPC exhibiting both venous and arterial involvement had a lower resection rate (odds ratio (OR) 0.22, p = 0.038). Isolated vein involvement and baseline cancer antigen (CA)19-9 levels < 500 kU/L predicted resectability (OR 5.99, p = 0.005) and survival (hazard ratio (HR) 0.47, p = 0.024). DPCG-BRPC demonstrated higher resectability rates (67.4% versus 46.9%, p = 0.004) and fewer vascular resections (37% versus 58%, p = 0.031) compared with NCCN-BRPC. While the NCCN only predicted resectability, DPCG also predicted survival. No patients with Lv type IIIc2-4 (nonreconstructable invasion of the portomesenteric vein combined with arterial involvement) underwent resection, and this subgroup had worse survival (HR 2.08, p = 0.021).
conclusionsVariations within established classification systems for BRPC/LAPC impact prediction of survival and resectability. A more detailed understanding of the anatomical subgroups in BRPC and LAPC, alongside CA19-9 levels, could enhance patient stratification regarding tumor resectability and neoadjuvant strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.